top of page

Search Results

Search results for "Caldan Therapeutics"

Results found for "Caldan Therapeutics"

Posts (319)

  • Why Intracellular Drugs May Hold the Key to GPCR Therapeutics

    diffusion, offset kinetics, and rebinding ✅ Real-world examples of how residence time—not potency—predicts therapeutic The slow-offset compound stays on target longer, maintains therapeutic effect as concentrations drop, DrugResidenceTime #AllostericModulation #CytosolicKinetics #PK #PD #CellPermeabilityAssays #PAMPA #Caco2 #TherapeuticKinetics

  • Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes

    adipose tissue size more effectively than exendin, suggesting that biased agonism can lead to distinct therapeutic In conclusion, biased agonism at the GLP-1R represents a promising strategy for optimizing therapeutic continues to grow, it is likely to play an increasingly important role in the design of next-generation therapeutics Christopoulos, Signalling bias in new drug discovery: detection, quantification and therapeutic impact Drucker, D.J., Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.  

  • Tectonic Therapeutic Strengthens Leadership Team

    July 2022 "July 19, 2022 07:00 AM Eastern Daylight Time BOSTON--Tectonic Therapeutic, Inc. a pre-clinical

View All

Other Pages (90)

  • Dr. Graeme Milligan | Dr. GPCR Ecosystem

    Milligan is the co-founder of both Caldan Therapeutics (2015) which discovers novel therapeutics for indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics

  • GPCR Desensitization in Health and Disease| Dr. GPCR Ecosystem

    and disease: homologous and heterologous mechanisms, regulation of the desensitization machinery, and therapeutic Coverage extends to the current state of GPCR desensitization in health and disease, including how certain therapeutics deleteriously regulate this machinery, the consequences for therapeutic efficacy, and strategies to knowledge of GPCR pharmacology whose work involves receptor regulation, loss of response, or sustained therapeutic β-arrestin-independent pathways, with the goal of identifying and targeting novel aspects of GPCR signaling for therapeutic

  • Dr. Josephine (Pina) Cardarelli | Dr. GPCR Ecosystem

    Pina Cardarelli, CSO for GPCR Therapeutics Inc., based in South Korea, has recently been named President of GPCR Therapeutics, USA, a newly incorporated Biotechnology company in the Bay Area. The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers She was an integral contributor to two therapeutics that are FDA approved, Yervoy and Opdivo. patents including anti-PD-1 patents, 22 EP patents, and greater than 100 global patents centered around therapeutic

View All

Events (2)

View All
bottom of page